Paladin Labs Inc. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 132

Paladin Labs Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Paladin Labs Inc. - Product Pipeline Review - 2012” provides data on the Paladin Labs Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Paladin Labs Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Paladin Labs Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Paladin Labs Inc. - Brief Paladin Labs Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Paladin Labs Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Paladin Labs Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Paladin Labs Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Paladin Labs Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Paladin Labs Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Paladin Labs Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Paladin Labs Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Paladin Labs Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Paladin Labs Inc.; Paladin Labs Inc. - Key Therapeutics; Paladin Labs Inc. - Pipeline Overview and Promising Molecules; Paladin Labs Inc. - News; Paladin Labs Inc. - Latest Updates; Paladin Labs Inc. - Pipeline; Paladin Labs Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Paladin Labs Inc. Snapshot
Paladin Labs Inc. Overview
Key Information
Key Facts
Paladin Labs Inc. – Research and Development Overview
Key Therapeutic Areas
Paladin Labs Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Paladin Labs Inc. – Pipeline Products Glance
Paladin Labs Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Paladin Labs Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Paladin Labs Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Paladin Labs Inc. – Drug Profiles
DDS-04F
Product Description
Mechanism of Action
R&D Progress
DDS-06E
Product Description
Mechanism of Action
R&D Progress
DDS-07L
Product Description
Mechanism of Action
R&D Progress
DDS-07U
Product Description
Mechanism of Action
R&D Progress
Estradiol + Testosterone Gel
Product Description
Mechanism of Action
R&D Progress
Fentanyl SDI
Product Description
Mechanism of Action
R&D Progress
Octreotide SDI
Product Description
Mechanism of Action
R&D Progress
Oralair
Product Description
Mechanism of Action
R&D Progress
Oxycodone + Acetaminophen
Product Description
Mechanism of Action
R&D Progress
Sancuso
Product Description
Mechanism of Action
R&D Progress
Sumatriptan SDI
Product Description
Mechanism of Action
R&D Progress
Tramadol + Acetaminophen
Product Description
Mechanism of Action
R&D Progress
Voclosporin
Product Description
Mechanism of Action
R&D Progress
Paladin Labs Inc. – Pipeline Analysis
Paladin Labs Inc. – Pipeline Products by Therapeutic Class
Paladin Labs Inc. – Pipeline Products By Target
Paladin Labs Inc. – Pipeline Products by Route of Administration
Paladin Labs Inc. – Pipeline Products By Mechanism of Action
Paladin Labs Inc. – Recent Pipeline Updates
Paladin Labs Inc. - Dormant Projects
QLT Inc. – Locations And Subsidiaries
Head Office
QLT Inc., Recent Developments
QLT Inc.- Press Release
Jun 17, 2009: Paladin Launches Twinject Twinpack For Anaphylaxis In Canada
Apr 02, 2009: Labopharm Reports Results For Phase III Study On Twice-Daily Tramadol-Acetaminophen Formulation
Mar 09, 2009: Paladin Files New Drug Submission For TRELSTAR
Financial Deals Landscape
Paladin Labs Inc., Deals Summary
Paladin Labs Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Paladin Labs To Acquire Tempra Product Portfolio From Bristol-Myers Squibb
Paladin Labs Acquires OTC Products From Wyeth Pharma
Paladin Labs Acquires Antizol, Antizol-Vet And Related Assets From Jazz Pharma
Paladin Labs Acquires Miltefosine Rights From AEterna Zentaris
Paladin Labs Acquires Zincofax From Johnson & Johnson
Paladin Acquires Products From Shire
Partnerships
Paladin Labs Enters Into Distribution Agreement With Common Sense
Paladin Labs Enters Into An Distribution Agreement With Protherics
Pfizer Amends Co-Marketing Agreement With Paladin Labs
Paladin Labs Forms Joint Venture With Isotechnika
Paladin Labs Enters Into Agreement With Sylphar
Paladin Labs Enters into Distribution Agreement With Mission Pharmacal
Paladin Labs Enters Into Distribution Agreement With GlaxoSmithKline
Paladin Labs Enters Into Co-Promotion Agreement With Procter & Gamble Pharma
Paladin Labs Enters Into Distribution Agreement With KV Pharma
Paladin Labs Enters Into Co-Promotion Agreement With Nycomed
Paladin Labs Expands Distribution Agreement With Shire HGT
Paladin Labs Enters Into Co-Marketing Agreement With Stallergenes
Paladin Labs Enters Into An Agreement With Verus Pharma
Paladin Labs Enters Into An Agreement With Watson Pharma
Paladin Labs Enters Into Co-Marketing Agreement With Duramed Pharma
Paladin Labs Enters Into Distribution Agreement With Ovation Pharma
Paladin Labs Enters Into Distribution Agreement With Transkaryotic Therapies
Licensing Agreements
Paladin Labs Enters Into Licensing Agreement With Immuron For Travelan
Somaxon Pharma Enters Into Licensing Agreement With Paladin Labs For Silenor
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group
Isotechnika Pharma Amends Its Licensing Agreement With Paladin Labs For voclosporin
Labopharm Enters Into Licensing Agreement With Paladin Labs
Paladin Labs Enters Into Licensing Agreement With SpePharm Holding
Isotechnika Pharma Enters Into Licensing Agreement With Paladin Labs
Paladin Labs Enters Into Licensing Agreement With ProStrakan
Paladin Labs Enters Into Licensing Agreement With Glide Pharma
Labopharm Enters Into A License And Distribution Agreement With Paladin Labs
Paladin Labs Enters Into Licensing Agreement With Pharmascience
Paladin Labs Enters Into Licenisng Agreement With Nuvo Research
Paladin Labs Enters Into Licensing Agreement With Duramed Pharma
Watson Pharma Enters Into Licensing Agreement With Paladin
Equity Offering
Paladin Labs Completes Private Placement For $40 Million
Paladin Labs Completes Public Offering Of $50.9 Million
Debt Offering
SpePharm Raises $5.42 Million In Private Placement With Paladin
Asset Transactions
Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline From Paladin Labs
Paladin Labs Sells T-ACTTM Platform To IMBiotechnologies
Acquisition
Paladin Labs To Acquire Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company
Litha Healthcare Group To Acquire Pharmaplan From Paladin Labs For $60.7 Million
Paladin Labs To Acquire Minority Stake In Litha Healthcare Group For $26.2 Million
Paladin Labs Completes Acquisition Of Labopharm
Paladin Labs Acquires 35% Stake In Pharmaplan
Paladin Labs Acquires Virexx Medical
Paladin Labs Acquires BioEnvelop
Paladin Labs Acquires Dimethaid Health Care
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Paladin Labs Inc., Key Information
Paladin Labs Inc., Key Facts
Paladin Labs Inc. – Pipeline by Indication, 2012
Paladin Labs Inc. – Pipeline by Stage of Development, 2012
Paladin Labs Inc. – Monotherapy Products in Pipeline, 2012
Paladin Labs Inc. – Combination Treatment Modalities in Pipeline, 2012
Paladin Labs Inc. – Filed, 2012
Paladin Labs Inc. – Phase III, 2012
Paladin Labs Inc. – Phase II, 2012
Paladin Labs Inc. – Phase I, 2012
Paladin Labs Inc. – Pre-Clinical, 2012
Paladin Labs Inc. – Discovery, 2012
Paladin Labs Inc. – Pipeline By Therapeutic Class, 2012
Paladin Labs Inc. - Pipeline By Target, 2012
Paladin Labs Inc. – Pipeline By Route of Administration, 2012
Paladin Labs Inc. – Pipeline Products By Mechanism of Action, 2012
Paladin Labs Inc. – Recent Pipeline Updates, 2012
Paladin Labs Inc. - Dormant Developmental Projects,2012
Paladin Labs Inc., Deals Summary
Paladin Labs To Acquire Tempra Product Portfolio From Bristol-Myers Squibb
Paladin Labs Acquires OTC Products From Wyeth Pharma
Paladin Labs Acquires Antizol, Antizol-Vet And Related Assets From Jazz Pharma
Paladin Labs Acquires Miltefosine Rights From AEterna Zentaris
Paladin Labs Acquires Zincofax From Johnson & Johnson
Paladin Acquires Products From Shire
Paladin Labs Enters Into Distribution Agreement With Common Sense
Paladin Labs Enters Into An Distribution Agreement With Protherics
Pfizer Amends Co-Marketing Agreement With Paladin Labs
Paladin Labs Forms Joint Venture With Isotechnika
Paladin Labs Enters Into Agreement With Sylphar
Paladin Labs Enters into Distribution Agreement With Mission Pharmacal
Paladin Labs Enters Into Distribution Agreement With GlaxoSmithKline
Paladin Labs Enters Into Co-Promotion Agreement With Procter & Gamble Pharma
Paladin Labs Enters Into Distribution Agreement With KV Pharma
Paladin Labs Enters Into Co-Promotion Agreement With Nycomed
Paladin Labs Expands Distribution Agreement With Shire HGT
Paladin Labs Enters Into Co-Marketing Agreement With Stallergenes
Paladin Labs Enters Into An Agreement With Verus Pharma
Paladin Labs Enters Into An Agreement With Watson Pharma
Paladin Labs Enters Into Co-Marketing Agreement With Duramed Pharma
Paladin Labs Enters Into Distribution Agreement With Ovation Pharma
Paladin Labs Enters Into Distribution Agreement With Transkaryotic Therapies
Paladin Labs Enters Into Licensing Agreement With Immuron For Travelan
Somaxon Pharma Enters Into Licensing Agreement With Paladin Labs For Silenor
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole
Paladin Labs Enters Into Licensing Agreement With ProStrakan Group
Isotechnika Pharma Amends Its Licensing Agreement With Paladin Labs For voclosporin
Labopharm Enters Into Licensing Agreement With Paladin Labs
Paladin Labs Enters Into Licensing Agreement With SpePharm Holding
Isotechnika Pharma Enters Into Licensing Agreement With Paladin Labs
Paladin Labs Enters Into Licensing Agreement With ProStrakan
Paladin Labs Enters Into Licensing Agreement With Glide Pharma
Labopharm Enters Into A License And Distribution Agreement With Paladin Labs
Paladin Labs Enters Into Licensing Agreement With Pharmascience
Paladin Labs Enters Into Licenisng Agreement With Nuvo Research
Paladin Labs Enters Into Licensing Agreement With Duramed Pharma
Watson Pharma Enters Into Licensing Agreement With Paladin
Paladin Labs Completes Private Placement For $40 Million
Paladin Labs Completes Public Offering Of $50.9 Million
SpePharm Raises $5.42 Million In Private Placement With Paladin
Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline From Paladin Labs
Paladin Labs Sells T-ACTTM Platform To IMBiotechnologies
Paladin Labs To Acquire Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company
Litha Healthcare Group To Acquire Pharmaplan From Paladin Labs For $60.7 Million
Paladin Labs To Acquire Minority Stake In Litha Healthcare Group For $26.2 Million
Paladin Labs Completes Acquisition Of Labopharm
Paladin Labs Acquires 35% Stake In Pharmaplan
Paladin Labs Acquires Virexx Medical
Paladin Labs Acquires BioEnvelop
Paladin Labs Acquires Dimethaid Health Care

List of Figures
Paladin Labs Inc. – Pipeline by Indication, 2012
Paladin Labs Inc. – Pipeline by Stage of Development, 2012
Paladin Labs Inc. – Monotherapy Products in Pipeline, 2012
Paladin Labs Inc. – Combination Treatment Modalities in Pipeline, 2012
Paladin Labs Inc. – Pipeline By Therapeutic Class, 2012
Paladin Labs Inc. - Pipeline By Target, 2012
Paladin Labs Inc. – Pipeline By Route of Administration, 2012
Paladin Labs Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Analysis of Yahoo! Inc
• Google
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Ixia - Company Analysis
• Priceline - Company Profile
• Analysis of Google Inc
• Dell Inc.
• Fiserv, Inc.